TR4DER - BAYER SCHERING PH [SCH.F] Interactive Chart for Technical Analysis

Watch more Technical Analysis charts

PS: The quotes after 2011-02-25 are still temporary and may have for that reason the Open values wrong until furter updates...
Change to BAYER SCHERING PH Static Chart

BAYER SCHERING PH - [Ticker: SCH.F]
Last Trade	0.00	Last Trade Time	- 00:00:00
Variation	N/A (N/A)	Open	0.00
High	0.00	Low	0.00
Volume	0	Average Volume (3m)	0
Yield		Bid / Ask	N/A
Former Close	0.00	52 Week Range	[0.00 - 0.00]
PER	0.00%	EPS	0.00
Ex-Dividend Date		Dividend Payment
Market Capitalization	0	1 Year Price-Target	0.00
Note: The data may have some minutes of delay.

News about BAYER SCHERING PH [SCH.F]: (ordered by relevance)

Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer Business Wire Legendary Bayer is Reinventing its Story with Cell and Gene Therapy BioSpace Bayer plans to stay the course amid investor pressure to split up, CEO says FiercePharma Bayer poaches GlaxoSmithKline exec to lead expanding oncology business?including a blockbuster hopeful FiercePharma New meds to drive growth of Bayer's Pharma business in Asia Pacific area BusinessMirror With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business?but for how long? FiercePharma Bayer CEO Baumann faces revolt from investor Temasek Holdings: report FiercePharma Merck counts 80-plus possible oncology drug approvals by 2028 FiercePharma JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more FierceBiotech Bayer's pharma business in Asia Pacific drives growth in 2021; More innovative medicines to be launched manilastandard.net Body plethysmographs of 2 manufacturers | COPD Dove Medical Press Bayer nabs yet another oncology leader from GSK to bolster cancer efforts FierceBiotech JPM 2022: Bayer taps CRISPR science from Doudna's lab in $1B biobucks Mammoth gene therapy deal FierceBiotech Bayer pulls plug on $670M CAR-T cell therapy pact with Atara in wake of patient death FierceBiotech ESC 2021: Bayer's Kerendia touts outcomes data as it looks to complement J&J, AZ drugs FiercePharma Bayer's Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patients FiercePharma The top 20 pharma companies by 2021 revenue FiercePharma 'The kidney medicine': Bayer touts Kerendia's blockbuster potential as its pharma group swings back to growth FiercePharma Bayer's new CKD treatment Kerendia approved in EU The Pharma Letter

For more news about BAYER SCHERING PH click here:
BAYER SCHERING PH News